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Abstract Regulators are increasingly mandating the use
of pharmaceutical risk-minimization programs for a variety
of medicinal products. To date, however, evaluations of
these programs have shown mixed results and relatively
little attention has been directed at diagnosing the specific
factors contributing to program success or lack thereof.
Given the growing use of these programs in many different
patient populations, it is imperative to understand how best
to design, deliver, disseminate, and assess them. In this
paper, we argue that current approaches to designing,
implementing, and evaluating risk-minimization programs
could be improved by applying evidence- and theory-based
‘best practices’ from implementation science. We highlight
commonly encountered challenges and gaps in the design,
implementation, and evaluation of pharmaceutical risk-
minimization initiatives and propose three key recommen-
dations to address these issues: (1) risk-minimization pro-
gram design should utilize models and frameworks that
guide what should be done to produce successful outcomes
and what questions should be addressed to evaluate pro-
gram success; (2) intervention activities and tools should be
theoretically grounded and evidence based; and (3) evalu-
ation plans should incorporate a mixed-methods approach,
pragmatic trial designs, and a range of outcomes. Regula-
tors, practitioners, policy makers, and researchers are
encouraged to apply these best practices in order to improve
the public health impact of this important regulatory tool.
Key Points
Although regulators are increasingly mandating
pharmaceutical risk-minimization programs,
insufficient attention has been given to maximizing
or measuring their effectiveness as public health
interventions.
Application of evidence- and theory-based
approaches from the field of implementation science
can increase the likelihood of program effectiveness
by guiding what should be done to produce
successful outcomes and what types of questions
should be asked to assess program success.
1 Introduction
Pharmaceutical risk-minimization programs are public
health interventions that are legally mandated in certain
countries as part of the pharmacovigilance strategy for
specific drugs. In essence, such programs are intended to
achieve a positive benefit-to-risk balance for these medi-
cations by ensuring that ‘‘the right prescriber provides the
right drug to the right patient at the right dose and at the
right time’’ under ‘real-world use’ conditions [1]. Risk-
minimization programs are often needed to gain more
insight into potentially concerning aspects of a product’s
safety profile. These programs can also enable regulators to
address unmet therapeutic needs by providing access to
medicines which, due to the significant risk(s) they pose to
patients, might not otherwise have been approved or per-
mitted to retain their marketing authorization.
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Risk-minimization programs, as a type of pharmaco-
vigilance tool, are designed, implemented, and evaluated
within the context of a heavily regulated environment. In
both the USA and the European Union (EU), the ability to
require risk-minimization programs is statutorily defined
[2, 3]. Regulatory guidances set forth recommendations for
risk-minimization program planning, implementation, and
evaluation [1–5]. These guidances also specify categories
of acceptable risk-minimization program intervention
components or ‘tools.’ Examples of the latter include
proactive communication [e.g., patient information leaflets,
Dear Healthcare Provider (HCP) letters], education and
training (e.g., educational programs, clinical decision
aides), and restrictions on prescribing and/or drug distri-
bution (e.g., HCP and/or patient certification, patient
informed consent or ‘safe use’ contracts).
Over the past decade, numerous risk-minimization pro-
grams have been implemented and evaluated for a range of
drug products across multiple therapeutic areas, and public
discussion and scrutiny of risk-minimization initiatives has
risen sharply [6–8]. To date, however, only a handful of
these programs have been shown to be effective [9–11]. As
a result, there is an urgent need to identify factors that
contribute to successful risk-minimization programs.
Efforts to do so, however, are stymied by the fact that
programs have been designed without reference to extant
theory, conceptual models and frameworks, or prior
research. In addition, the process and context of program
implementation are typically not systematically assessed or
reported, and evaluations have been inadequate in terms of
scope and methodologic rigor [9–11].
In recent years, there has been increased focus on
improving the effectiveness of a variety of pharmacovigi-
lance methods by introducing scientific approaches and
techniques borrowed from other fields [12, 13]. Similarly,
we argue that now is an opportune moment to advance the
practice of pharmaceutical risk minimization by applying
evidence- and theory-based methods from another disci-
pline, the field of implementation science. Implementation
science is the study of strategies to adopt and integrate
evidence-based health interventions and change healthcare
practice patterns within specific settings [14]. The field is
supported by a substantial and growing body of empirical
research [15, 16], a seminal textbook [17], dedicated US
Government websites [18, 19], and a journal [20].
As a discipline, implementation science emphasizes three
interacting factors which collectively influence program
effectiveness: the attributes of the proposed intervention, the
characteristics of the intended adopters, and aspects of the
intervention delivery context [21, 22]. These factors are
similarly critical for risk-minimization programs that aim to
integrate new practices or processes within the healthcare
system, target individual (e.g., patients, HCPs) and/or
organizational behavior change in order to adopt these new
practices, and involve implementation across numerous,
heterogeneous settings (e.g., home, clinic, specialty phar-
macy) and geographical areas [6, 7].
Greater attention to these three factors can improve the
overall quality, use, and impact of risk-minimization pro-
grams. For example, programs are more likely to be
adopted if they are perceived as adding value and integrate
easily within existing healthcare delivery processes.
Moreover, they are more likely to be effective if they are
implemented in a targeted and coordinated manner by
informed, committed stakeholders in settings that are
adequately resourced and supportive [21–23].
The purpose of this paper is to share ‘best practices’
from the field of implementation science and demonstrate
how they can be applied to pharmaceutical risk minimi-
zation. This effort is particularly timely given the recent
call for initiatives to identify and address knowledge gaps
for the prevention of adverse drug effects [24, 25]. The
application of implementation science methods offers
multiple advantages. First, it can provide a systematic and
comprehensive approach to conceptualizing, implement-
ing, and evaluating risk-minimization programs. Second, it
can spur development of an evidence base and facilitate
sharing of results across different risk-minimization ini-
tiatives. Third, it can enhance the likelihood that the
implementation strategies that are used are evidence-based
ones. Lastly, it can ensure that adequate and appropriate
data are collected for evaluation purposes, thereby
improving the evaluator’s ability to determine whether the
program was truly effective or not.
2 Areas to Improve Pharmaceutical Risk Minimization
We present recommendations from the perspective of
implementation science according to the phases of risk-
minimization program design, implementation, and evalu-
ation. This perspective is based on the collective learning
of the authors in reviewing, designing, conducting, and
evaluating numerous risk-minimization programs in the
USA and EU and their service on several US Food and
Drug Administration (FDA) advisory groups and profes-
sional working groups [26–32].
2.1 Risk-Minimization Program Design
Table 1 compares suggested ‘best practices’ from imple-
mentation science with current practices in risk-minimi-
zation program design. Further elaboration on these
proposed best practices is provided below.
Implementation science draws upon a variety of models
and frameworks to address different conceptual needs that










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Advancing the Field of Pharmaceutical Risk Minimization 571
arise at different phases of program design, implementa-
tion, and evaluation [33]. Three key conceptual needs at the
program planning phase pertinent to risk-minimization
initiatives are how to (1) design the program to produce
successful outcomes under real-world conditions; (2)
identify and select program intervention components that
will be most effective in changing individual and/or orga-
nizational behavior; and (3) determine the right questions
to ask in order to assess program success.
Intervention models or frameworks can be utilized to
address the question of how to produce successful program
outcomes and to ensure that program intervention compo-
nents, progress measures, and implementation processes
are integrated [33–35]. Intervention models emphasize the
use of specific intervention components or tools that have
been empirically demonstrated to be feasible, acceptable,
and effective. Evidence-based tools can be identified by
reviewing the medical, public health, and social marketing
literature (e.g., systematic reviews, meta-analyses, medical
guidelines, and state, federal and international information
resources). When existing evidence is limited or absent,
preliminary evidence can be generated regarding inter-
vention feasibility and acceptability via human factor
studies that simulate ‘real-world’ use conditions and/or
piloting conducted as part of the phase III clinical program.
Intervention models emphasize the importance of being
stakeholder-centered to enhance the likelihood that inter-
vention components will be acceptable and feasible to the
target audience and amenable to integration with existing
processes and systems [33–35]. To this end, risk-minimi-
zation planning should involve formative research with key
stakeholders to gather input on program design and strate-
gies for engaging stakeholders in the process of program
implementation and evaluation [33]. Key stakeholders
include patients, informal caregivers, the public, healthcare
providers, healthcare insurance purchasers, and payers [36].
Risk-minimization programs should also draw upon
relevant theories to guide conceptualization and selection
of individual intervention components, activities, or tools.
For example, behavioral theories have been used to guide
development of patient educational materials and training
programs [37], and to design computer-based decision-
support tools for physicians [38].
Interventions targeting multiple audiences and multiple
levels (i.e., the majority of risk-minimization programs to
date) are more likely to be effective and to yield clear
science-based results when guided by one or more theo-
retical models [33–35]. A theory-based approach enables
generation of testable hypotheses and the linking of pro-
gram results to a relevant empirical literature, providing
insight into how, when, and why a given risk-minimization
program was successful by shedding light on the mecha-
nism(s) of action responsible for program success.
Relevant models include those that address individual
behavior change (e.g., theory of planned behavior, theory
of reasoned action) [39, 40], communication processes
[41], and diffusion of innovation theories [42]. Social–
ecological models are also useful for linking program
components across different levels (e.g., individual patient,
healthcare setting, community) and can increase the like-
lihood that intervention impact will be more comprehen-
sive and sustained [43, 44].
A key—though largely under-recognized—challenge for
pharmaceutical risk-minimization program planning is how
to implement the program into actual practice under real-
world conditions in a manner that both preserves the
fidelity of the intervention as originally approved yet is
flexible enough to accommodate necessary local adapta-
tion. A potential reason why this issue has been under-
appreciated to date is that both regulators and industry drug
safety professionals are most familiar with clinical trials
and hence focus on issues of internal validity almost
exclusively. Risk-minimization programs, on the other
hand, need to maximize external validity in order to
achieve the desired impact and hence need to be designed
with dissemination in mind. Principles of ‘evaluability,’
which assess the likelihood that a program can be taken to
scale, should also be incorporated during the design pro-
cess [45].
To increase external validity, risk-minimization pro-
grams should be designed to incorporate active dissemi-
nation strategies. Active dissemination efforts, which
feature multiple communication methods targeting multi-
ple audiences and involving peer-to-peer human interac-
tion, have been empirically proven to be more effective
than passive strategies, such as printed pamphlets or
informational websites, alone [46, 47]. ‘Designing for
dissemination’ involves identifying the processes and fac-
tors that affect the adoption of a risk-minimization program
so as to increase the likelihood that a program will be
implemented and endorsed by local members and inte-
grated into existing practices and procedures [46, 47]. Key
adopter characteristics and contextual factors should be
identified as part of the program design and assessed during
the program evaluation [21].
To enhance the effectiveness of the information being
provided, risk communication messages should be
designed so as to address five dimensions: (1) identity (i.e.,
what is the harm associated with the risk); (2) probability
of risk occurring; (3) permanence of risk; (4) timing (i.e.,
when is it likely to occur); and (5) value (i.e., how much
does the consequence matter) [41]. Further information can
be found in an FDA evidence-based user’s guide for best
practices in communicating risks and benefits [48].
Numerous evaluation models and frameworks are useful
in guiding the design of risk-minimization program
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implementation, dissemination, and evaluation [10, 15, 16].
A recent review conducted by Tabak and colleagues [15]
identified 61 different models and frameworks and cate-
gorized them along three criteria: (1) construct flexibility
(ability to adapt and apply to a wide array of contexts); (2)
dissemination (spreading evidence) and implementation
(integration of evidence within a setting) continuum; and
(3) level of socio-ecological framework (healthcare system,
community, organization, or individual). Using these cri-
teria, the appropriate models and/or frameworks for a given
risk-minimization program can be identified and integrated
into the planning process. A guide to applying models and
frameworks is provided by the US Veterans Administration
Quality Enhancement Research Initiative (QUERI) [19].
Because risk-minimization programs typically need to
be carried out in a range of countries or locales where a
product is marketed, program adaptability is a critical
factor for successful local implementation [49]. As a result,
an important task during the design phase is to specify
which program components are essential or ‘core’ and
which are ‘non-core.’ Core components refer to specific
elements of the intervention that are critical to its effec-
tiveness. Non-core elements, sometimes referred to as the
‘adaptable periphery,’ are adaptable elements, structures,
and systems related to the risk-minimization program and
the organizational settings into which it is being imple-
mented [16]. For example, a prescriber training curriculum
could be identified as a ‘core’ element. While the training
curriculum would be considered a ‘core’ tool, the mode of
training delivery (e.g., via web, printed materials, or group
training) could be determined to be a ‘non-core’ element.
The program’s ‘adaptable periphery’ in this example would
be the training delivery modality which would be allowed
to vary in order to best suit the needs of each unique set-
ting. In general, local variations or refinements to non-core
elements should be encouraged as greater adaptability can
increase the likelihood that the program will continue to be
delivered as designed [21].
2.1.1 Case Examples
The Exalgo (hydromorphone HCl) risk-minimization
program to address product abuse is an example of a multi-
level program that was built around an alliance among
physicians, patients, and pharmacists and incorporated pre-
testing of programmatic elements. The design could have
been further strengthened through explicit use of a
behavioral change model to guide messaging [50, 51]. A
second example is that of Yervoy (ipilimumab), a product
that was approved in the USA for the treatment of late-
stage melanoma with a risk-minimization communication
program designed to address severe autoimmune reactions
[52]. The risk-minimization program was developed
synergistically with market launch and commercialization
planning activities, illustrating the concept of designing for
diffusion [52].
2.2 Program Implementation
Recommended best practices from implementation science
for use during program delivery and current practices in
pharmaceutical risk-minimization program implementation
are summarized in Table 2.
Risk-minimization programs can be challenging to
implement because implementation may need to occur at
multiple levels and/or be conducted by multiple parties.
Typically, risk-minimization programs are designed by
staff from the central office of the marketing authorization
holder (MAH) in conjunction with the requesting health
authority. For globally marketed products, however, it is
often staff at the affiliate offices who are actually respon-
sible for program implementation. For more complex risk-
minimization programs (e.g., prescriber certification,
restricted dispensing), an additional level of implementa-
tion may involve engaging with third-party vendors to
build specific program infrastructure (e.g., central data
collection repositories, patient service ‘hubs,’ and quality
monitoring systems). A final level may involve program
implementation within the actual healthcare system itself.
At each of these levels, implementation is dependent on
individuals who often have multiple competing priorities,
and who possess varying levels of motivation, expertise,
training, and access to needed resources.
Specific practices that can facilitate successful risk-
minimization program implementation include assessing
the implementing group’s ‘readiness-to-change,’ providing
tailored training and technical assistance to implementers,
identifying local ‘champions’ to initiate the program (from
both within local participating organizations as well as
targeted stakeholder groups), and establishing governance
processes to strengthen the collaborative links across all
levels of implementation [16, 53].
During the implementation process, there is a need to
monitor and document factors affecting the external
validity of risk-minimization programs so as to understand
the generalizability of the learning for other programs.
Multilevel process indicators that measure program reach,
adoption, implementation, fidelity, and costs/burden are
useful in this regard [35, 54]. Process measures, such as
reach and adoption, should be tracked in real-time during
program roll-out in order to identify and address problems
early on.
Contextual factors should also be collected as they can
serve as important mediators and moderators of program
effectiveness. Factors to assess include characteristics of
the key implementers (e.g., job title and professional













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































574 M. Y. Smith, E. Morrato
training, length of time in current role, prior experience
with and attitudes towards risk-minimization programs),
level of awareness, and degree of ‘buy-in’ from the local
healthcare provider community, features of the local
healthcare delivery and reimbursement system, and local
laws/regulations. Comprehensive process data can also
provide key information on the impact of different levels of
implementation, information that in turn can be valuable
for generating recommendations for future program mod-
ifications [54]. Additionally, it is important to document
the range of program adaptation or variations across all
sites and locations where the risk-minimization program
has been implemented.
Training and technical assistance should be provided on an
ongoing basis to offset the effects of staff turnover and risk-
minimization intervention ‘drift’ over time. Additionally,
establishing ‘communities of practice’ (CoPs) can facilitate
the exchange of best practices, promote engagement and
identity-building, and enhance program sustainability [55].
CoPs can be established as local, regional, or national advi-
sory boards comprised of healthcare delivery stakeholders in
a manner analogous to how medical advisory boards are
constituted to inform clinical development programs.
2.2.1 Case Examples
The use and type of implementation metrics for commu-
nication programs (e.g., reach, frequency, time on market)
is illustrated in two examples: (1) programmatic efforts to
reduce abuse of dextromethorphan by adolescents in the
USA [56]; and (2) in FDA’s ‘The Real Cost’ campaign to
reduce tobacco use among adolescents [57].
The risk-minimization program for warfarin, an oral
anticoagulant (marketed under the brand name of Couma-
din in the USA), is an example of a highly successful
program implementation process. Key tools in the risk-
minimization program included a computerized patient
tracking software application and educational materials.
Notably, prototypes for the risk-minimization materials
were initially developed by practicing clinicians. A rec-
ognition program for clinics demonstrating excellence in
improving quality of care for warfarin patients was used to
incentivize clinics to adopt the new tools. Indeed, results
showed that warfarin prescriptions continued to grow post-
program roll-out and that, ultimately, program elements
became integrated into standard of care for patients
receiving this product [58].
2.3 Program Evaluation
Key evaluation features, best practices in implementation
science, and current practices in risk-minimization program
evaluation are summarized in Table 3.
Due to the multilevel, multi-stakeholder nature of risk-
minimization programs, no single methodology is suffi-
cient for conducting a robust evaluation of program
implementation and impact. Qualitative methods are vital
for assessing the context of program delivery and for
characterizing the factors contributing to, or hindering,
program success, while quantitative methods are instru-
mental for assessing intervention impact. Thus, it is pref-
erable to utilize a combination of qualitative and
quantitative methods or a ‘mixed methods’ approach [59,
60]. An example of this approach can be seen in the
development of an enhanced FDA Patient Medication
Guide [61]. Focus groups were conducted to elicit detailed
qualitative input from patients regarding preferred features
of a Medication Guide; prototypes were developed, and
structured questionnaires were administered to obtain
quantitative assessments of patient comprehension and
information retention [61].
When using a mixed methods approach, there should be
a priori specification of (1) the order in which each method
will be used (e.g., sequentially or simultaneously); (2) the
priority of the methods (e.g., whether the approaches will
be equal or one will be the primary method); and (3) the
purpose of the methodological combination (i.e., for pur-
poses of convergence or complementarity) [59]. Multiple
different mixed methods design typologies are applicable
[59].
Current drug licensing requirements specify that risk-
minimization programs, as a type of post-approval com-
mitment, must be implemented fully once marketing
authorization has been granted. To date, MAHs have rarely
used experimental research designs for evaluating program
impact and instead have typically employed less scientifi-
cally robust methodologies that do not involve randomi-
zation [62]. It is not clear whether this reflects regulatory
dictates or industry preferences. Nonetheless, while ran-
domized clinical trial designs are high on internal validity,
results have limited generalizability. In contrast, practical
or ‘pragmatic’ trial designs address issues of both external
as well as internal validity by recruiting diverse, hetero-
geneous samples, including multiple and representative
settings and staff, using randomization, and assessing
multiple program outcomes (including behavior change) at
multiple program levels (e.g., organizational, patient, staff,
healthcare provider) [62, 63]. Alternatively, quasi-experi-
mental designs can be utilized (i.e., to capitalize on ‘natural
experiments,’ such as when one country has implemented
one version of a risk-minimization program while another
country has implemented a modified version of that same
program). In the absence of a comparator group, reference
data from phase III trial data and published literature can
aid in interpreting program impact as well by providing an
a priori threshold for program success [11, 64].





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































576 M. Y. Smith, E. Morrato
Some regulators may be receptive to using experimental
or quasi-experimental designs for the purposes of risk-
minimization evaluation; thus, MAHs should engage with
the appropriate health authorities early on in order to obtain
joint agreement as to the most feasible and scientifically
rigorous evaluation design to utilize. New ‘adaptive drug
licensing’ approaches also offer the promise of greater
flexibility in how risk-minimization programs may be
implemented and, hence, evaluated, in the future [64, 65].
Industry has an important role to play in advancing the
science in this domain as well by supporting the develop-
ment of new evaluation methods.
Currently, risk-minimization programs employ a limited
range of evaluation outcomes (e.g., knowledge, compre-
hension, clinical) [1, 3, 5–7]. Given the present status of
knowledge in this area, however, we argue that other types
of endpoints should be measured as well. These include
implementation and dissemination outcomes (e.g., extent to
which the targeted patient population was reached by the
intervention and extent to which the program was suc-
cessfully replicated in different settings), behavior change
(e.g., increases in frequency of prescriber counseling or
prescribing of specific screening or monitoring tests),
patient quality of life, and cost effectiveness. Outcome
measures should be practical, feasible, easy to collect, and
sensitive to change. Frequency of measurement should be
tailored to the individual attributes of each risk minimi-
zation. To minimize burden on both healthcare profes-
sionals and patients, existing data sources (e.g., electronic
medical records, prescription dispensing records, health-
care claims databases) should be leveraged to the full
extent possible [66, 67, 68].
Sharing of risk-minimization evaluation results is an
important way to promote dissemination of successful risk-
minimization interventions. Information on select risk-
minimization program evaluations can be found in advi-
sory committee documentation on the FDA’s website. The
new EU Post-authorisation Study (PAS) Register will be
posting the protocols and abstracts of results of risk-mini-
mization evaluation studies. Program evaluation results
should also be published in the peer-reviewed literature,
similar to what is done for clinical trial results.
2.3.1 Case Examples
The isotretinoin iPLEDGETM risk-minimization program
to prevent birth defects demonstrates a comprehensive
evaluation within the context of a closed distribution,
registry-based system. It includes implementation metrics,
assessment of knowledge and reported behaviors, and
health outcomes (pregnancies) [69].
The Risk Mitigation Action Plan (RiskMAP) for oxy-
codone extended-release (original formulation of
OxyContin) illustrates a mixed-methods approach to
program evaluation. Program impact was assessed using
data from poison control center calls, treatment program
admissions records, and law enforcement reports on drug
raids/seizures [70, 71]. Interviews were conducted with
drug abuse treatment experts, school and law enforcement
personnel and other local leaders [72]. These multiple
information sources and outcome measures provided a
richly detailed picture of the scope and nature of Oxy-
Contin abuse and were useful in guiding targeted inter-
vention efforts moving forward [72, 73].
3 Conclusion
Pharmaceutical risk-minimization programs, as currently
designed, implemented and evaluated, have yet to fulfill
their potential as public health interventions. We offer a set
of best practices from the field of implementation science
to address commonly encountered challenges (or gaps) in
the design, implementation, and evaluation of pharma-
ceutical risk-minimization initiatives. Two elements are
necessary to operationalize implementation science into
risk-minimization practice: access to behavioral science
expertise, and synergy with drug development and com-
mercialization activities. Industry can hire behavioral sci-
entists to work on product safety teams, or contract with
external experts. In addition, implementation science
approaches, if appropriately integrated into existing drug
development and post-marketing planning activities, pose
no special obstacle to the timely achievement of filings and
key post-marketing milestones. In sum, we encourage
regulators, risk-minimization practitioners, policy makers,
and researchers to apply implementation science best
practices in order to improve the public health impact of
this important regulatory tool.
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